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In-depth analysis of the cellular andmolecular mech-
anisms regulating human HSC function will require a
surrogate host that supports robust maintenance
of transplanted humanHSCs in vivo, but the currently
available options are problematic. Previously we
showed that mutations in the Kit receptor enhance
engraftment of transplanted HSCs in the mouse. To
generate an improved model for human HSC trans-
plantation and analysis, we developed immune-defi-
cient mouse strains containing Kit mutations. We
found that mutation of the Kit receptor enables
robust, uniform, sustained, and serially transplant-
able engraftment of human HSCs in adult mice
without a requirement for irradiation conditioning.
Using this model, we also showed that differential
KIT expression identifies two functionally distinct
subpopulations of human HSCs. Thus, we have
found that the capacity of this Kit mutation to open
up stem cell niches across species barriers has sig-
nificant potential and broad applicability in human
HSC research.
INTRODUCTION
Genetically altered mouse models are useful tools for functional
analysis of the biology of human hematopoietic stem and pro-
genitor cells (HSPCs) after the transplantation of HSPCs or hu-
man hematopoietic stem cells (HSCs), a condition referred to
as humanization (Doulatov et al., 2012; Shultz et al., 2012). AfterChumanization these mouse models make it possible to study
complex biological processes such as cell fate decisions, line-
age commitment, or immune function in an almost physiological
setting without a need for invasive procedures in healthy volun-
teers or patients.
A number of different mousemutants have been developed for
human HSPC functional analysis (Shultz et al., 2012; Willinger
et al., 2011). The most commonly used strains are immune-defi-
cient mice on BALB/c or NOD genetic backgrounds lacking T, B,
and NK cells. The different strains vary in terms of the quality of
engraftment of human HSCs (Shultz et al., 2012). In general,
NOD-based recipient strains (e.g., NOD Prkdc/ Il2rg/,
NSG) support higher levels of human HSC engraftment
compared to BALB/c-based recipients (e.g., BALB/c Rag1/
Il2rg/, BRg) (Brehm et al., 2010), apparently as a result of poly-
morphisms in the signal-regulatory protein alpha (Sirpa) gene,
which encodes a receptor that abrogates the phagocytosis of
human cells. BRg mice carrying a human Sirpa transgene are
able to show significantly enhanced human chimerism relative
to wild-type, but successful engraftment still requires irradiation
conditioning before HSC transplantation into newborn recipient
mice (Strowig et al., 2011). Thus, although the survival of human
HSCswas increased in these recipients, the availability of appro-
priate niches seemed to remain a limiting factor for successful
engraftment.
Alternative approaches to supporting long-term human HSC
engraftment have included overexpression of membrane-bound
human stem cell factor (SCF) (Brehm et al., 2012; Takagi et al.,
2012) and knockin of human thrombopoietin (Rongvaux et al.,
2011). Increased human chimerism was obtained in both cases,
but engraftment still depended on irradiation therapy of the
newborn hosts before transplantation (Brehm et al., 2012; Rong-
vaux et al., 2011; Takagi et al., 2012). Robust and long-term
maintenance of human HSCs after transplantation into adultell Stem Cell 15, 227–238, August 7, 2014 ª2014 Elsevier Inc. 227
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the study of human HSC function under steady-state conditions
using mouse models.
It is not clear whether modulation of specific signals or regula-
tory molecules would allow for more efficient replacement of
mouse HSPCs by their human counterparts in transplantation
studies. Previous chimera analyses in mice have shown that
the introduction of loss-of-function Kit alleles allows efficient
HSC engraftment in nonconditioned allogeneic recipient mice,
possibly because functional impairment of the endogenous
HSCs means that an irradiation conditioning step is not neces-
sary (Waskow et al., 2009). To investigate whether reduced Kit
function could have a similar effect for human HSC transplanta-
tion, we introduced a mutant Kit allele into immune-deficient
mouse strains on the BALB/c (BRg KitWv/Wv, BRgWv) or NOD
(NSG KitWv/Wv, NSGWv; NSG KitWv/+, NSGWv/+; and NSG
KitW41/W41, NSGW41) genetic backgrounds and analyzed
whether the HSC niche becomes permissive for human donor
HSCs in these animals. We found that human HSCs engraft effi-
ciently in these mice, even in adult nonconditioned recipients,
leading to sustained multilineage contribution that was main-
tained through serial transplantation. Thus, mice with mutations
in the Kit receptor are effective tools for analysis of human HSPC
function with significantly broader applicability than previously
existing models.
RESULTS
Efficient Engraftment of Human HSPCs into Kit Mutant
Mice without Irradiation Preconditioning
With currently available models, successful xenogeneic human
HSC transplantation into mice requires irradiation conditioning
before transplantation. Efficient engraftment without condition-
ing would be advantageous because irradiation has systemic
toxic effects on many cell types and impairs HSC function by
direct (Shao et al., 2014; Shen et al., 2012) and indirect (Carbon-
neau et al., 2012) mechanisms that may also impair the function
of donor HSCs (Nilsson et al., 1997). To investigate whether func-
tional impairment of the endogenous HSC compartment via mu-
tation of Kit could provide an advantage for the engraftment of
human HSCs, we bred a loss-of-function Kit allele (KitWv) into a
BALB/c Rag2- and Il2rg-deficient background already used for
human HSC transplantation (BALB/c Rag2 Il2rg KitWv/Wv
mice, referred to as BRgWv).We then tested the engraftment po-
tential of these mice by transplantation of CD34+-enriched
HSPCs from human cord blood into adult BRgWv mice without
prior irradiation conditioning, and we compared the engraftment
to similar mice lacking the Kit mutation that were transplanted
with and without prior irradiation. Chimerism 15 weeks after
transplantation was substantially higher in the blood of BRgWv
recipient mice compared to BRg recipients (Figure 1A) and
remained higher over a time period of 27 weeks (Figure 1B).
To assess whether the introduction of the mutant Kit receptor
opens up the stem cell niches for human HSCs irrespective
of the genetic background of the recipient, we compared the
contribution of human leukocytes to the blood of adult C57BL/
6 Rag2/ Il2rg/ KitWv/Wv (similar to the protocol in Waskow
et al., 2009) or BRgWv (Figure 1C) recipient mice. Human leuko-
cytes were readily detected in BRgWv, but not C57BL/6Rag2/228 Cell Stem Cell 15, 227–238, August 7, 2014 ª2014 Elsevier Inc.Il2rg/ KitWv/Wv, mice (Figure 1C), suggesting that differences in
the Sirpa allele (Strowig et al., 2011; Takenaka et al., 2007) or
other genetic modifier loci present in the BALB/c mouse strain
are advantageous for human HSPC engraftment in this context.
The frequencies of human leukocytes in the bone marrow of
BRgWv mice were uniformly very high and remained high over
time (Figure 1D). Notably, the engraftment rate at late time points
after transplantation was significantly increased compared to
irradiated NSG recipient mice (one of the best existing mouse
models; Shultz et al., 2012). Consistently, human leukocyte
numbers were higher in the bone marrow of BRgWv recipients
(Figure 1E), and engraftment was detected after the transplanta-
tion of as few as 1.2 3 104 human donor HSPCs (Figure 1F).
Thus, our data suggest that introduction of a mutant Kit allele
confers increased receptiveness for human cell engraftment in
the blood and bone marrow of recipient mice, and that this
receptiveness is improved to a sufficient extent to mean that effi-
cient engraftment can be achieved in adult recipient mice
without irradiation conditioning before transplantation.
SustainedMultilineageEngraftment byHumanHSPCs in
BRgWv Recipient Mice
To assess which human cell types were generated in the bone
marrow of recipient mice after transplantation, we analyzed the
recipient mice for the presence of human lymphoid, myeloid,
and erythroid lineage cells 11–37 weeks after human HSPC
transplantation into adult mice (Figure 2). Only B cells were de-
tected in the bonemarrow of nonconditioned BRgmice, and irra-
diation led to the additional appearance of monocytes and
granulocytes (Figure 2A). However, we were able to detect these
cell types at high frequencies after transplantation into nonirradi-
ated BRgWv recipient mice (Figure 2B). Detailed analyses of
myeloid cell types by flow cytometry (Figure 2C) combined
with morphological analyses confirmed the cellular identities
(Figure 2D) and revealed elevated repopulation of myeloid cell
types in BRgWv recipients compared to irradiated NSG and
BRg mice (Figure 2E). The composition of the myeloid cell types
of BRgWv and irradiated NSG recipient mice was comparable
(Figure 2F). These data suggest that nonconditioned BRgWv
mice support robust human myelopoiesis.
Human HSPCs transplanted into irradiated NSG mice can
give rise to erythrocytes, but this population has not yet been
described in strains with a BALB/c genetic background. In our
experiments, however, we were able to detect human erythroid
lineage cells in the bone marrow of 20 out of 29 BRgWv mice,
while only 8 out of 17 irradiated NSG recipients showed engraft-
ment with human erythroid cells (Figure 2G). Overall, therefore,
BRgWv recipient mice show long-term repopulation by myeloid
and erythroid cell types after human HSPC transplantation at
higher frequency than has been obtained thus far with existing
models.
De Novo Generation of Human Lymphocytes in
Transplanted BRgWv Mice
To test for continuous hematopoiesis from transplanted HSCs,
we analyzed B and T cell development in the bone marrow and
thymus, respectively, in the recipient mice. The developmental
stages of B cell development are defined by the status of D-J
or V-DJ recombination of the immunoglobulin heavy chain
Figure 1. Elevated Human White Blood Cell
Chimerism in the Bone Marrow of BRgWv
Mice following Human HSPC Transplan-
tation
(A) Dot plots show murine (mCD45) and human
(hCD45) leukocytes in nonconditioned BRgWv
and control BRg recipient mice that had received
33 105 human CD34-enriched cord-blood HSPCs
15 weeks earlier. Donor cell preparation and
number is the same for Figures 1B–1E.
(B) Frequencies of human leukocytes in the blood
of humanized BRgWv (n = 23), irradiated BRg
(n = 9), and nonconditioned BRg (n = 7) mice over
28 weeks of time.
(C) Frequencies of human leukocytes in the blood
of BALB/c RgWv (n = 5) or C57BL/6 RgWv (n = 4)
recipient mice treated as in (A).
(D) Frequencies of human leukocytes in the bone
marrow of BRgWv and control recipient mice
analyzed 17–24 weeks (left) or 25–37 weeks (right)
after transplantation of human HSPCs.
(E) Human leukocyte numbers in two femurs (left),
the spleen (middle), or in the thymus (right) of hu-
manized mice 17–37 weeks after transplantation.
Open symbols represent values detected in recip-
ient mice that were transplanted with sorter-puri-
fied human lineageCD38CD34+ cells.
(F) Frequencies of human leukocytes in the bone
marrow of BRgWv mice that had received indi-
cated numbers of human CD34-enriched HSPCs
19–24 weeks before.
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CD10, CD19, CD34, IgM, and IgD on the cell surface (Ghia
et al., 1996) (Figure 3A). In the bone marrow of reconstituted
BRgWv mice, we found that the CD19+CD10+CD34IgM pre
B cell compartment was overrepresented at the expense of
mature B cells (Figure 3B), suggesting that there is a defect
in B cell maturation that may be a result of species-specific
incompatibilities.
We also found that the mature T cell pool in the bone marrow
was small, but thymocyte numbers were greater in BRgWv
mice relative to control recipient mice, suggesting ongoing
T cell development (Figure 1E). In fact, the sizable fraction of
CD4+CD8+ (double positive, DP) human thymocytes that we
observed in BRgWv mice (Figures 3C and 3D) is similar to the
situation seen in transplanted irradiated NSGmice and in thymus
biopsies from human infants. We also detected DP thymocytes
after transplanting cell-sorter purified human lineageCD38
CD34+ cells into nonconditioned BRgWv and irradiated NSG
recipient mice (Figure 3D, open symbols), suggesting that theseCell Stem Cell 15, 227–2cells could be generated de novo from en-
grafted human HSCs. Clear evidence for
de novo T cell generation in BRgWv mice
came from the analysis of T cell receptor
excision circles (TRECs) in the thymocytes
of the recipient mice (Figure 3E). Thymo-
cytes from repopulated thymi, but not
from control thymi, could proliferate in
response to polyclonal T cell stimulation
(Figure 3F).To confirm that the continuous human hematopoiesis that
we observed was based on HSC activity and not on the differ-
entiation of cotransplanted progenitor cells, we transplanted
sorter-purified lineageCD38CD34+ cord blood HSPCs and
determined their multilineage differentiation potential. We found
donor-derived myeloid and erythroid cells in the bone marrow
(Figures 3G–3I) and short-lived T cell precursors in the thymus
as described above (Figure 3D, open symbols), suggesting
that at the time point of analysis de novo hematopoiesis was
occurring. Overall, therefore, we conclude that continuous hu-
man lymphopoiesis is supported in BRgWv recipient mice.
Enhanced Self-Renewal of Human HSCs in Mice Is a
Function of Mutant Kit
We next looked at whether the mouse bone marrow microenvi-
ronment in Kit mutant recipients is permissive for the self-
renewal of human HSPCs by examining the localization and
phenotype of the transplanted cells (Figure 4A). We found that
human HSPCs engrafted in the bone marrow, but not in the38, August 7, 2014 ª2014 Elsevier Inc. 229
Figure 2. Multilineage Repopulation of Humanized Mice
(A) Human cell types that engrafted in the bone marrow of indicated mouse strains after the transplantation of 3 3 105 human CD34-enriched HSPCs 29 weeks
earlier. Human CD3+ T, CD19+ B, SSChi granulocyte, and CD14+ monocyte cell populations were superimposed on SSC/FSC dot-plots. Donor cell preparation
and number is the same throughout Figure 2.
(B) Relative composition of human-graft-derived leukocytes in the bone marrow of recipient mice of the indicated genotypes that received human HSPC 11–
37 weeks earlier. For comparison the relative composition of BALB/c murine bonemarrow is shown. Human cells were identified as CD3+ T, CD19+ B, and CD33+
myeloid cells, and immature cells lacking the expression of CD3, CD19, and CD33. Mouse cell types were identified as CD45R+ B cells, CD3+ T cells, CD11b+
myeloid cells, and lineage (lineage = CD3 CD11b CD19) immature cells. Number of mice analyzed per group is indicated above each column.
(C) Identification of indicated cell types in the bone marrow of humanized BRgWv mice 27 weeks after humanization (top) and control human bone marrow
(bottom). Arrow indicates population that is shown in the next dot plot. pDC, plasmacytoid dendritic cells; cDC, conventional DC; Baso, basophil granulocyte; Eo,
eosinophilic granulocyte; MC, mast cell; PMN, polymorph nucleated neutrophil; NP, neutrophil precursors.
(D) Pictures show May-Gru¨nwald-Giemsa stained cells of the indicated lineages (purified as described in A and C) purified from human bone marrow and from
humanized BRgWv mice that were transplanted with human HSPCs 14 weeks earlier. Size bar applies to all photographs.
(E) Plot shows frequencies of human myeloid cells (CD33+ cells) in the bone marrow of indicated humanized mice that were transplanted with human HSPCs
20–37 weeks before.
(F) Composition of human myeloid cells in irradiated NSG and BRgWv recipient mice.
(G) Frequencies of human erythroid cells (hCD45mCD45Ter119hCD235+) in humanized mice 14–37 weeks after transplantation.
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Figure 3. Lymphocyte Differentiation in Humanized BRgWv Mice
(A) B cell development in human bone marrow (top) or in bone marrow and spleen of BRgWv mice (middle and bottom, respectively) that had received 3 3 105
human CD34-enriched HSPCs 28 weeks before. Dot plots depict the expression of CD19 and CD10 on human leukocytes (hCD45+ SSClo, left), the expression of
IgM and CD34 on CD19 CD10 double positive cells (middle), and the expression of IgM and IgD on CD19 single positive cells (right). Donor cell preparation and
number is the same in Figures 3B and 3F.
(B) Frequencies of pro-B cells (BI, CD10+CD19+CD34+IgM), pre-B cells (BII, CD10+CD19+CD34IgM), immature B cells (BIII, CD10+CD19+CD34IgM+), and
mature B cells (BIV, CD10CD19+CD34IgM+) of total B cells (CD19+) in the femurs of BRgWv or irradiated BRg mice transplanted with human HSPCs
21–32 weeks earlier.
(C) Dot plots show the expression of CD4 and CD8 on hCD45+ CD3+ thymocytes of a humanized BRgWv mouse 23 weeks after transplantation and human
thymus control (donor age: 5 months). Data shown are representative for five independent experiments.
(D) Plot shows the frequency of CD4+CD8+ double positive thymocytes in humanized mice of the indicated genotype that had received 33 105 CD34-enriched
(closed symbols) or 3 3 104 sorted (lineageCD38CD34+, open symbols) human HSPCs 16–31 weeks before.
(E) Relative frequency of T cell receptor excision circles (TRECs) in thymocytes of humanized BRgWv mice that were transplanted as described in (D). TREC
frequencies were determined in purified T cells (CD3+) from human cord blood (CB) and blood (PB) samples from adult donors (age: 44–58 years) for control.
(F) Plot shows 3H-thymidine incorporation into thymocytes after in vitro trigger with PHA. Thymocytes from transplanted BRgWv (Tx) mice, but not from non-
transplanted control BRg (w/o) mice, expanded after polyclonal trigger.
(G) Dot plot shows repopulated bone marrow 17 weeks after transplantation of 3 3 104 sorter-purified lineageCD38CD34+ human HSPCs (purity: 99.8% ±
0.23%, three independent experiments; human CD45+ cells: 59.4% ± 28%, n = 6 mice.)
(H)Graph shows composition of human bonemarrow graft 16, 17, and 30weeks after transplantation as described in (G). Data shown are as described in Figure 2B.
(I) Sorter-purified donor cells give rise to erythroid cells.
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Figure 4. Maintenance of Human HSCs in
Mice
(A) Dot plots show human HSPCs (CD38CD34+)
within immature cells (lineage, cells lacking CD2
CD3 CD10 CD11b CD14 CD15 CD16 CD19
GlyA expression) of human origin (hCD45+) in the
bone marrow of nonconditioned BRgWv or non-
conditioned or irradiated BRg or NSG recipient
mice, and in a human bone marrow control sample.
Recipient mice were analyzed 19 weeks after
transplantation of 3 3 105 human CD34-enriched
HSPCs. Donor cell preparation and number is the
same in Figures 4B–4E.
(B) Plot shows numbers of human HSPCs (hCD45+
lineageCD34+CD38) in two femurs of humanized
indicated mouse strains transplanted 11–37 weeks
before.
(C) Human HSPCs were further analyzed for the
expression of CD90 and CD45RA in indicated hu-
manized recipient mice and human bone marrow
control.
(D) Plot shows frequencies of human HSCs
(% lineageCD38CD34+CD90+CD45RA) in indi-
cated mouse strains and human control samples.
(E) Plot shows numbers of human HSPCs in the
bone marrow 27–32 weeks after humanization of
newborn mice with 3 3 105 CD34-enriched cord
blood cells.
(F) Dot plots show engrafted human cell types in the
bonemarrow of secondary recipientmice 13weeks
after transplantation of 107 total bone marrow cells
from primary recipient mice. Cells were identified
as shown in Figure 2A.
(G) Frequencies of human CD45+ cells in the bone
marrow of secondary recipient mice 11–20 weeks
after secondary transplantation of 1 to 23 107 total
bone marrow cells from primary recipient mice. The
number of positively repopulated mice out of all
secondary recipients is indicated.
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marrow was more efficient in BRgWv mice than in irradiated
BRg or NSG recipients (Figure 4B). Recent analyses have
indicated that within the CD38CD34+ compartment, human
HSCs can be more precisely defined as CD90+CD45RA
cells (Majeti et al., 2007) (Figure 4C). The frequency of
lineageCD38CD34+CD90+CD45RA HSCs was significantly
higher in the bone marrow of BRgWv recipients compared to
irradiated NSG recipients (Figure 4D). In fact, frequencies of hu-
man HSCs in reconstituted BRgWv mice were equivalent to that
in human bonemarrow, suggesting that the HSCniche in BRgWv
mice is suitable for the maintenance of human HSCs (Figure 4D).
Increased maintenance of human HSCs was also observed after
transplantation into newborn BRgWv mice, suggesting that the
improved accessibility of niche space for human HSCs brought232 Cell Stem Cell 15, 227–238, August 7, 2014 ª2014 Elsevier Inc.about by the Kit mutation is independent
of the age of the recipient mice (Figure 4E).
To determine whether these phenotypi-
cally defined human HSCs were func-
tional, we conducted serial transplantation
of total bone marrow cells from primary
recipient mice into secondary recipients.Secondary transplantation into BRgWv mice was successful
and led to the presence of detectable human B cells, NK cells,
monocytes, and granulocytes. By contrast, we found mainly B
cells in the bone marrow of irradiated BRg secondary recipients
(Figure 4F). The number of successfully repopulated secondary
BRgWv recipient mice (18 out of 28 recipients) was greater
than the success rate with irradiated BRgmice (5 out of 13 recip-
ients) receiving a graft from primary recipient mice of the same
genotype (Figure 4G). Moreover, the frequency of human leuko-
cytes in the bone marrow was increased in secondary BRgWv
recipients compared to secondary irradiated BRg recipients,
confirming the improved maintenance of functional multipotent
human HSCs in primary BRgWv recipients.
Taken together our data show efficient and effective mainte-
nance of phenotypic and functional human HSCs in the bone
Figure 5. Kit Receptor Regulates Competi-
tion between Human and Mouse HSCs and
HPCs
(A) Plot shows immature mouse bone marrow
cell numbers (CD3CD11bCD19CD45RGr-
1NK1.1Ter119) in nontransplanted (w/o Tx) or
indicated humanized mouse strains (Tx) that had
received 3 3 105 human CD34-enriched HSPCs
12–37 weeks earlier.
(B) Homing of human CD34-enriched HSPC cells
into the bone marrow of indicated recipient mice
within 18 hr after transplantation.
(C) Relative mRNA expression levels of the trans-
membrane (tm) or soluble (s) forms of SCF in niche
cells (CD45Ter119CD31Pdgfra+CD51+) from
nontransplanted BRgWv and BRg mice. Each dot
represents the mean of triplicate analysis from one
mouse.
(D) Concentration of stem cell factor (SCF) in blood
and bone marrow of nontransplanted mice of the
indicated genotypes determined by ELISA. Each
dot represents the mean of duplicate analysis from
one mouse. As a positive control, increased SCF
protein levels in complete Kit null mice are shown
(KitW/W hEPO-tg; Waskow et al., 2004).
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tations, and that the level of functional engraftment that can be
achieved in these mice is significantly improved relative to exist-
ing host mouse strains.
Mechanism of Human Stem Cell Maintenance
To assess whether the engrafted human immature hematopoiet-
ic cells replace precursor cells of murine origin, we determined
the number ofmouse progenitors in the bonemarrow of recipient
mice (Figure 5A). We found that the murine progenitors were
significantly reduced in numbers in the bone marrow of trans-
planted BRgWv recipients, but not in irradiated NSG or BRg
recipients, suggesting that the clone size of human HSPCs
increased in humanized BRgWv mice because human donor
cells are able to compete effectively with the endogenousmouse
cells. Thus, human cells with a fully functional KIT receptor may
have a proliferative advantage over mouse HSPCs expressing a
mutant Kit allele.
The increased engraftment rates in the BRgWv mice were in-
dependent of any alteration of homing activities (Figure 5B) or
of changes in the availability of the ligand for the Kit receptor,
SCF, (Figures 5C and 5D), which can modulate the engraftment
of human donor cells in mouse models (Brehm et al., 2012;
Takagi et al., 2012). The protein level of SCF was comparable
between Kit mutant and wild-type recipient mice (Figure 5D).
Also, the relative abundance of SCF transcripts encoding
the membrane-bound or soluble form of SCF in marrow mesen-
chymal stromal cells, the nonhematopoietic niche cell fractionCell Stem Cell 15, 227–2that expresses SCF, was similar in mice
carrying wild-type or mutant Kit alleles
(Figure 5C). These findings suggest that
the increased engraftment of human
HSCs is based on impaired murine
HSC function that results in increasedaccessible niche space for donor humanHSCs, and that it allows
human HSCs to out-compete endogenous HSCs for niche
space.
Expression of Mutant Kit Increases the Receptiveness
of NSG Mice for Human HSC Engraftment
To investigate the capacity of BRgWv mice for human HSC
engraftment, we looked at transplantation of very high donor
HSC numbers and found elevated engraftment compared to irra-
diated NSGmice (Figure 1D), suggesting that BRgWv mice have
more available niche space for human HSCs than NSG mice do.
Consistently, we find increased endogenous HSC numbers in
nontransplanted, Kit wild-type BRg mice compared to NSG
mice (Figure S1A available online), suggesting that immune-defi-
cient mice on the BALB/c genetic background have more HSC
niches. To compare the engraftment of human donor cells under
nonsaturating conditions, we looked at transplantation of limited
numbers of donor HSPCs. In this experiment we saw increased
engraftment of human leukocytes in irradiated NSG mice
compared to nontreated BRgWv recipients (Figure 6A), prompt-
ing us to test whether mutant Kit also confers an advantage for
the engraftment of human HSCs in NOD-based mouse strains.
We generated three more mouse strains: NSG KitWv/+ (termed
NSGWv/+), NSG KitWv/Wv (termed NSGWv), and NSG KitW41/W41
(termed NSGW41), and we also transplanted them with human
HSPCs. A large fraction of the NSGWv mice became moribund
and were not available for analysis (Figure 6B). We continued to
use the NSGWv/+ and NSGW41 mouse strains, which survive38, August 7, 2014 ª2014 Elsevier Inc. 233
Figure 6. Mutant Kit Confers Increased
Receptiveness on the NOD Genetic Back-
ground
(A) Plot shows human leukocyte frequencies in the
bone marrow of BRgWv and irradiated NSG
recipient mice 30 weeks after the transplantation
of indicated titrated numbers of sorted human
lineageCD38CD34+ cord blood HSPCs.
(B) Survival plot for humanized nonconditioned
BRgWv, NSGWv/+, NSGWv, and NSGW41
recipient mice after the transplantation of 3 3 105
(BRgWv) or 3 to 5 3 104 (NSGWv, NSGWv/+,
NSGW41) CD34-enriched human HSPCs.
(C) Frequencies of human leukocytes in the blood
as a function of the frequency of human leukocytes
in the bonemarrow for the indicatedmouse strains
15–40 weeks after transplantation of 3 3 105
(closed circles) or 3 to 53 104 (open circles) CD34-
enriched human HSPCs.
(D) Frequency of human myeloid cells within the
bone marrow of humanized mice 15–40 weeks
after the transplantation of 3 to 5 3 104 CD34-
enriched cord blood cells.
(E) Plot shows relative composition of human-
graft-derived leukocytes in the bone marrow of
recipient mice 15–40 weeks after transplantation
of 3 to 5 3 104 CD34-enriched human HSPCs.
(F) Kinetic of the repopulation in the blood of
NSGW41 and irradiated NSG recipient mice after
the transplantation of 103 (left) or 104 (right) human
CD34-enriched HSPCs. Data from two indepen-
dent experiments are pooled (103 donor cells were
transplanted in six irradiated NSG and eight
NSGW41 mice; 104 donor cells were transplanted
in five irradiated NSG and seven NSGW41 mice).
See also Figure S1.
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cipients showed very uniform and robust engraftment with hu-
man donor cells, and blood chimerism reflected the engraftment
frequency in the bone marrow (Figure 6C). In NSGW41 mice, we
saw increased generation of myeloid cells (Figure 6D) and an
improved balance between T and B lymphocytes (Figure 6E)
compared to standard irradiated NSG recipients. However, as
in the BRgWv mice, cells of the B lymphoid lineage were also
blocked in their terminal differentiation (data not shown). Trans-
plantation of titrated numbers of donor cells into irradiated NSG
andnonconditionedNSGW41mice revealed an increased recep-
tivenessofNSGW41micecompared to irradiatedNSGrecipients
(Figure 6F), similar to the situation that we saw when comparing
BRgWv to irradiated BRg mice. Consistently, the SCID repopu-
lating cell (SRC) activity in CD34-enriched HSPCs was found
to be increased in NSGW41 recipient mice (irradiated NSG: 1 in
4,732, NSGW41: 1 in 514; p = 0.001), suggesting an enhanced
sensitivity for the engraftment of human HSCs. Thus, it seems
that Kitmutation also enables efficient human HSC engraftment234 Cell Stem Cell 15, 227–238, August 7, 2014 ª2014 Elsevier Inc.in the immune-deficient NOD genetic
background without a requirement for
irradiation preconditioning.
To test whether the increased levels of
engraftment seen in the Kit mutant mouse
strains makes them suitable for studiesusing the human immunodeficiency virus type 1 (HIV-1), we
repopulated newborn irradiated NSG mice and adult noncondi-
tioned NSGWv/+ and NSGW41 mice using StemReginin1-
expanded human HSCs, and we infected them 20 weeks later
with HIV. The viral load was determined 4, 7, and 9 weeks post-
infection and proved to be comparable between all three human-
izedmouse strains (Figure S1B). This analysis therefore suggests
that the NSGWv/+ and NSGW41 mouse strains would be highly
suitable for studies using HIV.
Adoptive Transfer of Prospectively Separated Human
Stem Cell Populations Reveals Two Functional
Subpopulations in the Human HSC Pool
We then looked at whether NSGWv/+ recipientmice can be used
to assay human HSC function. Subtle differences in the density
of Kit receptor expression on the surface of murine HSCs are
associated with strikingly different functions (Grinenko et al.,
2014; Shin et al., 2014). More specifically, HSCs expressing in-
termediate levels of Kit (Kitint) show more potent engraftment
Figure 7. Two Functional Subpopulations of Human HSCs
(A) Prospective separation of Kithi and Kitint human HSCs from cord blood (left
and middle) and postsort analysis of both populations before transplantation
(right).
(B) Repopulation of mouse blood by human leukocytes (human CD45+) over
the time course of 30 weeks after transplantation of sorter-purified
lineageCD38CD34+CD90+CD45RA Kithi or Kitint human HSCs in NSGWv/+
recipient mice.
(C) Frequency of human HSPCs (CD38CD34+) in the bone marrow (hCD45+)
of NSGWv/+ mice that had received purified Kithi or Kitint HSCs 30 weeks
before. Data from two independent experiments were pooled.
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represent consecutive developmental stages. Thus, the transi-
tion from Kitint to Kithi HSCs indicates the initiation of differentia-
tion (Grinenko et al., 2014). To assesswhether the level of KIT cell
surface receptor expression also allows the prospective separa-
tion of two discrete HSCpopulations in humans, we transplanted
sorted cord blood HSCs expressing high or intermediate levels
of KIT into nonconditioned NSGWv/+ mice (Figure 7A). Human
HSCs expressing high densities of KIT showed higher repopula-
tion activity for human leukocytes in the blood of the recipient
mice over time compared to KITint human-cord-blood-derived
HSCs (Figure 7B). This higher contribution in the blood was
based on more efficient engraftment of human HSCs in the
bonemarrow, where the progeny of KIThi humanHSCswere pre-
sent at a higher frequency compared to KITint-derived human
HSCs (Figure 7C). Interestingly, this situation is reversed relative
to that seen in mouse where Kitint HSCs are the best at repopu-
lation, suggesting that the role of Kit-mediated signals differs be-
tween the two species generally or that it shifts during ontogeny
in the same organism. We conclude that KITint and KIThi cells are
two functionally distinct human HSC subpopulations that can be
distinguished based on their repopulation capacity in this mouse
model.
DISCUSSION
We show here that combining a loss-of-function allele of the Kit
receptor with profound immune deficiency allows the efficient
and stable engraftment of human HSCs into adult recipientCmice without a need for prior irradiation. Our data suggest that
the Kit mutation functionally impairs endogenous HSCs in a
way that permits efficient engraftment of human HSCs, and
they show that this approach is effective in immune-deficient
strains with BALB/c or NOD genetic backgrounds.
Existing mousemodels used for xenogeneic HSC transplanta-
tion require irradiation conditioning before transplantation to
deplete the endogenous HSCs and provide niche space for the
donor HSCs (Shultz et al., 2012). Engraftment without condition-
ing would be advantageous because irradiation has systemic
toxic effects on many proliferating cell types (Shao et al., 2014;
Shen et al., 2012; Carbonneau et al., 2012), and the induced
inflammation may have a major impact on the level and quality
of engraftment and on immune-mediated complications (e.g.,
graft versus host disease). Our approach was designed to facil-
itate human HSC engraftment in mice by increasing the HSC
niche space through impairment of the endogenous mouse
HSCs by introducing a loss-of-function Kit allele. Using this
approach, we found that human HSPCs successfully engrafted
into three strains of immune-compromised mice, BRgWv,
NSGWv/+, and NSGW41, and that successful reconstitution of
secondary recipient mice provided evidence for functional main-
tenance of human HSCs. Furthermore, NSGWv/+ and NSGW41
mice are very suitable mouse models for the study of HIV and
possibly other human pathogens. Taken together, we conclude
that functional impairment of endogenous host murine HSCs us-
ing Kit mutation conveys a competitive advantage for incoming
human stem and progenitor cells and allows the engraftment
of human HSCs into adult mice without irradiation conditioning.
Engraftment of human HSCs into mice of a young age is
generally considered advantageous (Brehm et al., 2010; Shultz
et al., 2007), and newborn BRg or NSG are successfully used
for the generation of humanized mice harboring all components
of the innate or adaptive immune system (Ishikawa et al., 2005;
Ito et al., 2002; Rongvaux et al., 2014; Traggiai et al., 2004). How-
ever, our experiments reveal no advantage for human HSC
engraftment in newborn versus adult BRgWv recipient mice.
In principle, it seemed to us that mutation of the Kit receptor
could provide an advantage for the engraftment of human
HSCs in mice through two distinct mechanisms: a direct impair-
ment of endogenous HSCs that allows their replacement by
donor cells and/or increased expression of SCF caused by
impaired ligand-receptor interactions in cells expressing Kit.
However, in BRgWv mice we found that SCF protein levels and
transcripts in bone marrow niche cells are unaltered, suggesting
that the increased HSC engraftment in these mice is indepen-
dent of SCF expression/availability. In line with this hypothesis,
prior work has shown that increased levels of human SCF
can support increased differentiation, but not engraftment of
human HSCs (Brehm et al., 2012). We therefore propose that
the increased engraftment that we observe is based largely
on impaired murine HSC function, resulting in accessible niche
space for human HSCs. Thus, our experiments suggest that
the Kit receptor is a regulator of HSC competitiveness across
species.
Recently a number of mouse strains have successfully been
generated that show improved engraftment of human myeloid
cell types by harboring overexpression or knockin approaches
for human growth factors (Miller et al., 2013; Rongvaux et al.,ell Stem Cell 15, 227–238, August 7, 2014 ª2014 Elsevier Inc. 235
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increased myeloid differentiation achieved by these approaches
may well be achieved at the expense of HSC maintenance,
suggesting that human cytokine levels must be finely tuned to
provide appropriate differentiation signals and allow stem cell
maintenance at the same time (Nicolini et al., 2004). Direct com-
parison to Kit wild-type mice revealed significantly increased
generation of myeloid cells in Kit mutant NSGW41 or BRgWv re-
cipients, suggesting that improved engraftment of human HSCs
in the murine stem cell niche also leads to an improved engraft-
ment of myeloid cell types. Also, mouse progenitor cells in the
bone marrow were largely replaced by human hematopoietic
progenitors, pointing at a proliferative advantage for human
cells expressing a fully functional Kit receptor over mouse cells
expressing mutant Kit. We conclude that increased myeloid
cell contribution can also be achieved through improved HSC
engraftment and a competitive proliferation advantage of human
myeloid progenitor cells.
We repopulated nonirradiated NSGWv/+ mice with human
HSCs that were prospectively separated into cells expressing
high and intermediate densities of the KIT receptor, and through
this analysis we found that the human HSC pool can be subdi-
vided into two cell populations that functionally differ in their
engraftment capacity. Human HSCs expressing high densities
of KIT (KIThi) containmore potent repopulation activity compared
to HSCs expressing intermediate levels (KITint). In contrast, in
mice Kitint HSCs exhibit a very efficient engraftment activity,
and the reduced signaling activity by the Kit receptor seems
crucial for the maintenance of ‘‘stemness’’ in situ (Grinenko
et al., 2014). It will be interesting to determine in the future
whether this difference is due to distinct species-specific re-
quirements for Kit signaling or due to some switch altering the
relevance of the level of Kit signaling during ontogeny (Kawa-
shima et al., 1996).
When our data are taken together, our overall conclusion
is that impairment of endogenous host HSCs by Kit receptor mu-
tation leads to a competitive advantage for incoming human
stem and progenitor cells and allows efficient engraftment of
human HSCs into adult mice without irradiation conditioning.
In this study we have generated three mouse strains, BRgWv,
NSGWv/+, and NSGW41 mice, that take advantage of this
approach and facilitate analysis of human HSC function. Based
on these results, we would expect thesemice to also be superior
to irradiated mice for the transplantation of leukemic cells, which
have proved difficult to engraft efficiently in xenotransplantation
models. We are planning to explore this line of investigation in
future experiments. Finally, our data also suggest that Kit might
be an attractive target for approaches aimed at facilitating HSC
engraftment without prior conditioning in human therapeutic
settings.
EXPERIMENTAL PROCEDURES
Mice
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (NSG) were obtained from Jackson
Laboratory. C57BL/6Rag2/ Il2rg/KitWv/Wv (Figure 1C)mice were obtained
by intercrossing Rag2/ Il2rg/ KitWv/+ mice (Waskow et al., 2009), and
KitWv/Wv offspring were identified by their white coat color. BRgWv mice were
generated by backcrossing the KitWv allele (C57BL/6-Kit < Wv > ) to N10–
N20 onto the H-2d (BALB/c haplotype) Rag2tm1Alt Il2rgtm1Brn strain (Kirberg236 Cell Stem Cell 15, 227–238, August 7, 2014 ª2014 Elsevier Inc.et al., 1997), which is permissive for humanization (Scheeren et al., 2008).
The latter strain is N4 with respect to BALB/c and had been maintained
by inbreeding before the introduction of theKitWv allele.KitWv andKitW41 alleles
werebackcrossed toNSGmice for 18and10generations, respectively. Result-
ing BALB/c Rag2/ Il2rg/ KitWv/+ or NSG KitWv/+ mice were intercrossed to
obtain the experimental homozygous BRgWv or NSGWvmice. Also NSGWv/+
mice were used for transplantations. To genotype for Kit alleles (Kit<+>,
Kit<Wv>), PCR was performed on tail-snip DNA (forward: 50-AAAGAGAG
GCCCTAATGTCG; reverse: 50-CTCGAGACTACCTCCCACC) and the prod-
ucts were sequenced using the forward primer (Kit<Wv> harbors a C to T con-
version at position 2007; Nocka et al., 1990) or by digestion of a PCR product
with NsiI (forward: 50- CCACGCTTTGTTTTGCTAAAATGCATCAC; reverse:
50- AGGCACTGCCTAAATCATACTTTGATAACC; PCR mix volume: 11 ml). A
band of 182 bp is indicative for the wild-type allele and bands of 118 bp and
64 bp are indicative for the Kit<Wv> allele. KitW41 allele typing was by PCR
(forward: 50-AAGGAAGGTTAGAACCCCTGG; reverse: 50-AGCTCCCAGAGGA
AAATCCC). The products were sequenced using the forward primer. The
Kit<W41> allele contains a point mutation at position 2519 (G/ A) (Nocka
et al., 1990). All mice were bred and maintained under specific pathogen-free
conditions at the animal facility of theDresdenUniversity of Technology. Animal
experiments were approved by the relevant authorities, the Landesdirektion
Dresden.
Human Donor Cells
Human umbilical cord blood samples were provided by the DKMS Cord Blood
Bank Dresden and by the Department of Hematology/Oncology, University
Hospital Dresden and were used in accordance with the guidelines approved
by the Ethics Committee of theDresdenUniversity of Technology. Two to six in-
dividual cord blood samples were pooled before Ficoll-Hypaque density centri-
fugation andmagnetic enrichment for CD34+ cells according tomanufacturers’
instructions (Miltenyi Biotech). Purity of CD34+ cells was on average 93%± 4%
(n = 23). In indicated experiments sorted human HSCs were transplanted. The
sort was lineage (lineage = CD2 CD3 CD10 CD11b CD14 CD15 CD16 CD19
CD56 CD235) CD38 CD34+ and the purity was 99.8% ± 0.2% (n = 3) by
FACS Aria III (BD). Human thymi were obtained from living children undergoing
heart surgery and were used in accordance with the guidelines approved
by the Ethics Committee of the University Hospital of Erlangen. Single-cell
suspensions were obtained by tissue disruption and Collagenase D digestion.
Thymocytes were further purified by gradient centrifugation on Bicoll.
Flow Cytometry
Bonemarrow, spleen, and thymus cell suspensionswere prepared and stained
as described (Arndt et al., 2013; von Bonin et al., 2013). Leukocyte counts
of cells of mouse (mCD45+) or human (hCD45+) origin were determined
by analyzing viable cells (DAPI, 4,6-diamidino-2-phenylindole, Molecular
Probes) usingMACSQuant Analyzer (Miltenyi). Human cellswere stained using
antibodies specific for (clone names given in parentheses) the following: CD10
(HI10A), CD11c (3.9), CD16 (3G8), CD45 (HI30), CD117 (A3C6E2), CD203
(NP4D6), CD235 (HIR2), IgM (MHM-88), and NKp46 (9E2) (all BioLegend);
CD2 (RPA-2.10), CD3 (UCHT1), CD4 (RPA-T4), CD8 (RPA-T8), CD10
(eBioSN5c), CD11b (CBRM1/5), CD14 (M5E2), CD15 (HI98), CD16 (CB16),
CD19 (HIB19), CD33 (WM-53), CD38 (HIT2), CD45RA (HI100), CD56
(MEM188), CD123 (6H6), CD125 (A14), and CD235a (HIR2) (all eBioscience);
and CD34 (581/CD34), CD38 (HIT2), IgD (IA6-2), CD90 (5E10), CD125 (A14),
IgD (IA6-2), TCRab (T10B9.1A-31), and TCRgd (11F2) (all BD Biosciences).
Reagents specific for mouse antigens were as follows: CD3 (2C11), CD11b
(M170), CD19 (eBio1D3), CD31 (390), CD45 (30-F11), CD45R (RA3-6B2),
Gr-1 (RB6-8C5), NK1.1 (PK136), CD51 (RMV-7), CD140a (APA5), CD144
(eBioBV13), Gr-1 (RB6-8C5), and Ter119 (Ter-119) (all eBioscience). Samples
were acquired or sorted using an LSRII or Aria III cytometer (BD Biosciences),
respectively, and were analyzed using FlowJo software (Tree Star).
Transplantations
Adult recipient mice (4–12 weeks of age) were transplanted with (BRg 400cGy,
NSG 200cGy; X-Ray source, MaxiShot, Yxlon) or without irradiation condition-
ing (BRgWv, BRg, NSGWv, NSGWv/+, NSGW41) prior to intravenous injection
of 103 to 3 3 105 CD34+-enriched cord blood cells (HSPCs) or 3 3 104 sorted
lineageCD38CD34+ cells in 150 ml PBS/5% FCS. Alternative donor cell
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software as previously described (Grinenko et al., 2014) scoring nonre-
sponders as mice that showed <2% hCD45+ cells in the bone marrow 24–
26 weeks after transplantation of 5 3 104, 104, and 103 CD34-enriched cord
blood HSPCs into NSGW41 or irradiated NSG mice. Pairwise differences in
active cell frequencies between groups were calculated as described previ-
ously (Hu and Smyth, 2009). Newborn recipientmice (1–3 days old) were trans-
planted with (BRg 300cGy, NSG 75cGy) or without irradiation conditioning
(BRgWv or BRg) prior to intrahepatical (i.h.) transfer of 33 105 CD34+-enriched
cord blood cells in 30 ml volume. For secondary transplantations 1 to 2 3 107
nonseparated bone marrow cells were injected per recipient. To assess the
function of prospectively separated human HSC populations, 1,000 (experi-
ment 1) or 6,000 (experiment 2) sorted lineageCD38CD34+CD90+CD45RA
Kithi or Kitint human HSCs were transplanted into 3- to 5-week-old non-
conditioned NSGWv/+ recipient mice. After transplantation mice were given
neomycin-containing drinking water for 3 weeks. For the homing assay, 4 or
7 3 105 human HSPCs were transplanted into adult recipient mice (n =
8–12) with or without previous irradiation (850cGy) and human CD34+ cell
numbers in two femurs were determined 18 hr later. The number of human
HSPCs detected in the bone marrow was normalized to the number of trans-
planted cells.
Polyclonal Stimulation of Thymocytes
Thymocytes of humanized BRgWv and control BRgWv or BRg mice were
cultured in 200 ml RPMI with or without Phytohemagglutinin (PHA, 1 mg/ml,
Sigma Aldrich) for 72 hr, and subsequently 1 mCi 3H-thymidine (Hartmann An-
alytic) was added for 18 hr. The incorporation of 3H-thymidine was quantified
using a beta counter (Perkin Elmer). Data are presented as fold changes in the
numbers of PHA treated-cells relative to untreated controls.
Morphological Analysis
Cells were sorted and cytospun (500 3 g, 5 min) onto glass slides and were
stainedwithMay-Gruenwald-Giemsaasdescribedbefore (Waskowetal., 2008).
SCF ELISA
Levels of mouse SCF in serum and bone marrow were determined using the
Quantikine mouse SCF ELISA Kit (R&D) according to the manufacturer’s in-
structions. We prepared bone marrow samples by crushing two femurs in
500 ml PBS and centrifuging to remove cells and bone splinters. Blood samples
were allowed to clot for 2 hr at room temperature before centrifugation. All
samples were stored at 20C and assayed within 1 month of collection.
Molecular Analysis
TREC analysis was performed as follows: genomic DNAwas isolated using the
RNA-Bee (Ams Biotechnology #CS-104B) following the manufacturer’s in-
structions. Relative TREC levels were determined using primers and condi-
tions as described (Hazenberg et al., 2000). PCRs were performed in triplicate
on a Stratagene Mx3500P qPCR Cycler (Agilent). TREC frequencies were
calculated using the DDCt method. Average frequency of TRECs in T cells
from adult donors (40–70 years) was set to 1 to calculate the relative frequency
of TRECs in cord blood CD3+ T cells and in thymocytes from BRgWv recipient
mice. For SCF RT-PCR, bone marrow cells were digested with 0.25%
collagenase type I and 1 mg/ml DNase I at 37C. Nonhematopoietic cells
(CD45Ter119) were enriched (Miltenyi), and for RNA isolation (RNeasy
MicroKit; QIAGEN) 3,000 CD45Ter119CD31PDGFRa+CD51+ MSCs were
sorted (purity: 98.6% ± 1.1%, n = 11). cDNA was synthesized using the
SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen). qPCR re-
actions were run in triplicate for each sample in 20 ml of reaction mix including
2 ml of cDNA, SYBR green (Fermentas), and 0.1 mM of the following primers.
Soluble (s) SCF: forward, 50-CTCTCTTCAACATTAGGTCCCGAGAAAGA
TTCCA; reverse, 50-CTTCCAGTATAAGGCTCCAAAAGCAAAGCCA; trans-
membrane (tm) SCF: forward, 50-CTCTTCAACATTAGGTCCCGAGAAAGG
GAAAG; reverse, 50-CTTCCAGTATAAGGCTCCAAAAGCAAAGCCA; GAPDH
forward, 50-AAGGGGCGGAGATGATGAC; reverse, 50-GGTGCTGAGTATGTC
GTGGAG. Annealing temperatures of 60C were used. Incorporation of SYBR
green was analyzed using the Mx3005P QPCR system (Agilent) and theMxPro
QPCR Software (MxPro, version 4.10). SCF transcript level was normalized on
GAPDH expression.CStatistical Analysis
A two-tailed Student’s t test was used for all statistical analysis. *p = 0.05–0.01,
**p = 0.01–0.001, and ***p < 0.001. Mean ± standard deviation is shown
throughout figures.
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